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Mediators of myocardial in￿ ammation, predomi-
nantly cytokines, have for many years been
implicated in the healing processes after infarc-
tion. In recent years, however, more attention has
been paid to the possibility that the in￿ ammation
may result in deleterious complications for myo-
cardial infarction. The proin￿ ammatory cyto-
kines may mediate myocardial dysfunction
associated with myocardial infarction, severe con-
gestive heart failure, and sepsis. A growing body
of literature suggests that in￿ ammatory mediators
could play a crucial role in ischemia±reperfusion
injury. Furthermore, ischemia±reperfusion not
only results in the local transcriptional and
translational upregulation of cytokines but also
leads to tissue in￿ ltration by in￿ ammatory cells.
These in￿ ammatory cells are a ready source of a
variety of cytokines which could be lethal for the
cardiomyocytes. At the cellular level it has been
shown that hypoxia causes a series of well
documented changes in cardiomyocytes that in-
cludes loss of contractility, changes in lipid
metabolism and subsequent irreversible cell
membrane damage leading to cell death. For
instance, hypoxic cardiomyocytes produce inter-
leukin-6 (IL-6) which could contribute to the
myocardial dysfunction observed in ischemia±
reperfusion injury. Ischemia followed by reperfu-
sion induces a number of other multi-potent
cytokines, such as IL-1, IL-8, tumor necrosis
factor-a (TNF-a), transforming growth factor-b1
(TGF-b1) as well as an angiogenic cytokine/
growth factor, vascular endothelial growth factor
(VEGF), in the heart. Intrestingly, these multi-
potent cytokines (e.g. TNF-a) may induce an
adaptive cytoprotective response in the reper-
fused myocardium. In this review, we have in-
cluded a number of cytokines that may contribute
to ventricular dysfunction and/or to the cytopro-
tective and adaptive changes in the reperfused
heart.
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Myocardial Ischemia and
Reperfusion
Coronary artery disease is one of the most
common cardiac disease and it takes a heavy toll
of lives in industrialized countries. Stenosis of a
coronary artery leads to the myocardial ischemia
which provokes tissue injury that could be
reversible or irreversible depending on the
severity and duration of myocardial ischemia. In
the case of reversible tissue injury, structural
and functional properties of the myocardium
completely recover after reperfusion, whereas
after irreversible injury, tissue does not recover
upon reperfusion and the myocardium becomes
necrotic.1,2 The occurrence of myocardial infarc-
tion during an acute coronary occlusion indi-
cates not only the lack of oxygen and blood
supply but also the disruption of defense and
adaptive mechanisms of the myocardium against
ischemia. Myocardial responses to a critical
coronary stenosis in terms of adaptation and
defense could be (1) long lasting (hours to days)
contractile dysfunction in the absence of any
cell death (stunned myocardium);3,4 (2) toler-
ance towards ischemia after a short period of
supply±demand mismatch (preconditioned
myocardium); 5,6 (3) myocardial angiogenesis i.e.
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collateral circulation;7,8 and ￿nally, (4) atrophy
of cardiac myocytes in chronic coronary artery
disease.9
Molecular Phenotype of
Reperfused Myocardium
Myocardial ischemia can induce an adaptive and
angiogenic process which consists of a number
of sequential events including endothelial cell
proliferation, migration and tissue in￿ltration;
these processes are probably regulated by poly-
peptide growth factors and cytokines. Recently,
we and others have reported that brief periods
of ischemia leave myocardium stunned without
cellular necrosis.3,4,10 Stunning swine myocar-
dium with two cycles of a 10 min left anterior
descending coronary artery (LAD) occlusion
followed by reperfusion increases tolerance to a
subsequent longer period (60 min) of ischemia.6
T o get an insight into the myocardial molecular
response in ischemic reperfused swine myocar-
dium, we studied the expression pattern of a
number of genes which could play a pivotal role
in cytoprotection and adaptation in the heart.
These were the proto-oncogenes (c-myc, c-fos,
c-jun, and egr-1),11 heat shock proteins (HSPs;
HSP-70, HSP-27, HSP-32, HSP-8),6,9,12 calcium
regulatory proteins13,14 and angiogenic growth
factors.7,15,16 Proto-oncogene products have
been implicated in almost every aspect of
growth control, from the binding of growth
factors to cell surface receptors, to signal
transduction and the regulation of transcrip-
tion.11,17,18 HSPs are a highly conserved group
of cellular proteins which are expressed in
almost every type of organism from bacteria to
man.19,20 HSP-70 binds to ATP and helps in
translocating cytoplasmic proteins in the cells
and HSP-27 migrates to the nucleus in response
to stress, acts as molecular chaperone and plays
an important role in signal transduction.19,21- 25
A number of groups, including ours, have
reported that myocardial ischemia and reperfu-
sion induce HSP-70 and HSP-27.6,9,21,25 Brief
periods of myocardial ischemia in rabbits also
cause a rapid expression of HSP-70, which is
detectable at the protein level within 2 hours.26
Physiological relevance of such induced HSPs is
believed to provide myocardial cytoprotection
and adaptation after an ischemic epi-
sode.20,23,25,27,28 Ubiquitin, another highly con-
served small HSP was found to be up-regulated
in the reperfused myocardium.10,29 It is believed
that enhanced expression of ubiquitin in re-
sponse to stress is followed by its reversible
conjugation with abnormal proteins destined for
degradation. 29- 31 W e believe that brief coronary
occlusions±reperfusions would cause molecular
damage in cardiac myocytes and such damage
requires the involvement of HSPs in rescuing
several vital proteins and restoring myocardial
function. In contrast, irreversible myocardial
damage requires rapid disposal via the ubiquitin
system (ubiquitination and subsequent proteoly-
sis) to ensure proper functioning of the surviv-
ing cells. Anti-oxidative enzyme systems (such as
catalase and Mn
2+ SOD) have also been impli-
cated in the adaptive mechanisms underlying
myocardial ischemia±reperfusion.32 Very re-
cently, we have shown that myocardial ischemia
and reperfusion lead to the induction of heme
oxygenase-1 (also known as HSP-32), an enzyme
that generates antioxidant biliverdin; the stimu-
lus for its en- hanced expression appears to be
oxygen free radicals.12,33
Expression of Cytokines in the
Heart
Transforming growth factor-b1
Transforming growth factor-b1 (TGF-b1) is a
25 kDa homodimeric polypeptide differentiation
factor found in platelets and most organs,
including the heart.34- 36 By using reverse tran-
scriptase±polymerase chain reaction (RT±PCR)
and Northern blot analysis, we have shown that
chronic myocardial ischemia resulted in en-
hanced expression of TGF-b1 mRNA.15 In situ
hybridization studies revealed that TGF-b1 spe-
ci￿c mRNA transcripts were predominantly
localized in cardiac myocytes near ￿brotic tissue
and not in the area of the in￿ammatory in￿l-
trate.36 Furthermore, immunoblot analysis with
a polyclonal anti-TGF-b1 antibody showed a
speci￿c band of 25 kDa in myocardial protein
extracts from normal and chronically ischemic
hearts.36 Immunoreactive TGF-b1 was localized
in the cardiomyocytes. Purkinje cells of the
conduction system were consistently stained
with TGF-b1 speci￿c antibodies15,36 indicating
that TGF-b1 may in￿uence the degree of differ-
entiation in these cells. The cellular source of
TGF-b1 in the heart is controversial. Thompson
et al.34 found TGF-b1 mRNA and protein in the
cardiac myocytes of the infarcted tissue,
whereas Eghbali35 demonstrated mRNA expres-
sion of TGF-b1 only in the nonmyocyte fraction
of cardiac tissue.
Although TGF-b1 is an inhibitor of endothelial
cell proliferation it has been found to be
angiogenic when injected subcutaneously into
newborn mice37 or when applied locally in
wound healing experiments.38 The angiogenic
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indirect one, the primary response is the chemo-
attraction for monocytes which then, in turn,
stimulate angiogenesis.37,39 TGF-b1 has been
shown to contribute to myocardial protection
during ischemic injury;40 a single bolus dose of
TGF-b1 to a rat markedly protected the heart
against reperfusion injury as assessed by loss of
myocardial creatinine kinase activity and a re-
duction in circulating TNF-a levels.41 Studies
suggest that TGF-b1 might be an important
molecule in cardiac embryogenesis, hypertro-
phy, atherogenesis, healing of myocardial infarc-
tion and in the development of coronary
collaterals.34,36,39,41,42 TGF-b1 also maintains the
contractility of cultured cardiomyocytes and
blocks the supressive effects of IL-1 on their
beating rate by down-regulating the expression
of NO-synthase.43 Thus, TGF-b1 could be a
clinically important cytokine in the treatment of
reperfusion injury and in￿ammatory disease in
the heart.
Tumor necrosis factor-a
Tumor necrosis factor-a (TNF-a) is a 17 kDa
multipotent cytokine produced mainly by acti-
vated macrophages that has been implicated in
several biologic processes including in￿amma-
tion, immunoregulation, and angiogenesis.44 It
acts directly on vascular endothelium as well as
on cardiomyocytes to increase the adhesion of
leukocytes during in￿ammation.45,46 TNF-a is
similar in many ways to TGF-b as both polypep-
tides induce angiogenesis in vivo, promote tube
formation in vitro, but inhibit endothelial cell
proliferation; this indicates that TNF-a is an
indirect angiogenic growth factor which may
stimulate other cells to produce angiogenic
factors such as VEGF .45- 47 Biological effects of
TNF-a in the target cell (cardiomyocytes) are
initiated by its binding to high af￿nity cell
surface receptors.48- 50 TNF receptors channel
signals to cytoplasm and nucleus, and thereby
initiate profound alterations in the metabolic
pathway and nuclear transcription.51 By using
RT±PCR, we detected mRNAs encoding TNF-a
in the porcine normal as well as ischemic
myocardium. 15 By Northern hybridization, we
observed that TNF-a speci￿c mRNA expression
was induced in the ischemic myocardium as
compared with the level found in normally
perfused myocardium.15 Expression of TNF-a
and its receptors has been shown in failing
human hearts indicating a pivotal role for this
cytokine in pathogenesis.52,53 Furthermore, the
literature suggests that TNF-a mRNA is tran-
scribed in the adult heart at a detectable level
and may play a role in the in￿ammatory
processes caused by myocardial ischemia.
TNF-a induced cytoprotective
mechanisms in the heart
Dysfunction of the coronary endothelium as
well as injury to cardiac muscle cells are the
consequences of myocardial ischemia and
reperfusion. Among many factors, TNF-a is
also released into the postischemic myo-
cardium.41,54,55 These ischemia-induced cyto-
kines may mimic local cellular injury and may
contribute to the changing molecular phenotype
of the postischemic myocardium. An increase in
both local expression and circulating TNF-a has
been reported in experimental animals and in
patients with myocardial ischemia and in-
farction.54,55 Interestingly, pretreatment of rat
hearts with TNF-a was found to be protective
against ischemia and reperfusion injury.56 How-
ever, in the normal heart, TNF-a may exert
negative inotropic effects by directly altering
intracellular calcium homeostasis in a concentra-
tion- and time-dependent manner.57 Many stud-
ies have demonstrated that TNF-a induces
phosphorylation of a stress protein of about
28 kDa in a number of cell types including
cardiomyocytes58- 60 and this phosphorylation
results from stimulation of a G protein-coupled
signal transduction pathway involving the mito-
gen activated protein (MAP) kinase.61- 62
Perfusion of spontaneously contracting cul-
tures of cardiomyocytes with a high dose of
TNF-a (10,000 units/ml) led to arrhythmias and
complete cessation of spontaneous contractions
followed by severe loss of myocyte inotropy.63 It
is known that TNF-aas well as interleukins (IL-2,
IL-3, IL-6) induce the formation of stress proteins
in cultured cardiomyocytes.23,58,64 HSPs partici-
pate in cellular defense mechanisms and enable
cells to survive and recover from stressful
conditions.19,24,27,28 It is believed that the heart
has its own endogenous system(s) for protecting
itself against ischemia±reperfusion injury and a
number of HSPs that may act as chaperones in
saving vital cellular proteins from degradation
have been proposed.21- 28 We tested the hypoth-
esis that TNF-a stimulates cytoprotective me-
chanisms in cardiomyocytes; such mechanisms
can be examined by investigating the expression
pattern of various stress protein genes. In an in
vitro model based on cultured cardiomyocytes
treated with TNF-a we examined gene expres-
sion of several HSPs (HSP27, HSP70 and ubi-
quitin).64 TNF-a induced arrhythmia and
cessation of spontaneous contractions in both a
concentration- and time-dependent manner. By
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that steady state (ubiquitin) or undetectable
mRNA levels (HSP27, HSP70) were drastically
increased as compared to the untreated control
cells; the effects of TNF-a were maximal at 6±
8 h of stimulation after which the expression of
these stress genes declined. By Western blot
analysis we found increased multiple bands of
ubiquitin±protein conjugates in TNF-a treated
cells, but no signi￿cant change in HSP27 protein
accumulation was observed until 12 h. After
24 h incubation with TNF-a partial cellular
necrosis was detected; hence, the induced ex-
pression of cytoprotective molecules such as
stress proteins (HSP27, HSP70 and ubiquitin) in
response to TNF-a may activate protective and/
or repair mechanisms in cardiomyocytes which
may make them more resistant toward a subse-
quent challenge such as ischemia. It appears that
TNF-a, on the one hand, mimics cellular injury
in the heart and on the other it stimulates
synthesis of vital proteins like HSPs and Mn2+
SOD making it a very interesting and relevant
cytokine for the cardiovascular system. Further-
more, the ubiquitin system could play an im-
portant role in cytosolic degradation of damaged
proteins in TNF-atreated cardiomyocytes where
HSPs may counteract the proteolytic events and
preserve many vital proteins. Thus, induction of
genes conferring resistance to the cytotoxic
property of TNF-a may provide a means by
which cardiomyocytes can defend themselves
under pathophysiological conditions.
Interleukin-1
Interleukin-1 (IL-1) is a multifunctional cytokine,
primarily involved in the regulation of in￿amma-
tory processes; it mediates most of the acute-
phase response to infection including induction
of fever.65 Recent evidence indicates that IL-1
produced within tissues contributes to local
in￿ammatory reactions.66 Other biological activ-
ities of interleukin-1 include induction of ￿bro-
blast growth, ICAM-1 expression and growth
and differentiation of Band Tcells.67 Two genes
are expressed for IL-1: IL-1aand IL-1b. Although,
these genes show only 20±30% amino acid
homology they were shown to bind the same
high-af￿nity receptor.68 IL-1 does not posses a
typical hydrophobic signal sequence for secre-
tion and may be processed extracellularly by
limited proteolysis from a high molecular mass
intracellular precursor of 33 kDa to an active
17 kDa form.69,70 IL-1 is produced mainly by
macrophages/monocytes, T cells, B cells, ￿bro-
blasts, keratinocytes, astrocytes and endothelial
cells67 and has a wide range of target cells
including cardiomyocytes and vascular smooth
muscle cells. It also induces prostanoid-depen-
dent hypotension in rabbits in vivo71 and
stimulates human smooth muscle cells to se-
crete interleukin-6.72 In chronically ischemic
myocardium where focal necrosis was documen-
ted, enhanced levels of IL-b mRNAs were found
indicating a role of this cytokine in myocardial
in￿ammation.15 Han and co-workers73 have ob-
served unchanged IL-1b mRNA expression in
non-failing and failing human heart by RT±PCR.
IL-1b induces macrophage-type nitric oxide
synthase gene expression in cardiomyocytes
leading to de novo synthesis of NO in the
heart.74 Treatment of rat hearts with IL-1a
resulted in improved ventricular systolic pres-
sure and overexpression of Mn2+ SODresulting
in reduced ischemia±reperfusion injury.75
Interleukin-6
Interleukin-6 (IL-6), a secreted single chain
protein of 28 kDa, located on chromosome 7 in
human and on chromosome 5 in mouse, is
another pluripotent cytokine.67 It is released
from a variety of cell types including mono-
cytes/macrophages, ￿broblasts and endothelial
cells. 67,76 Recently, it was shown that IL-6 is also
expressed by vascular smooth muscle cells in
atherosclerotic lesions of genetically hyper-
lipidemic rabbits.77 IL-6 has a wide variety
of biological functions including induction of
B-cell differentiation and acute-phase re-
sponse.78,79 Treatment of cultured rat vascular
smooth muscle cells with recombinant IL-6
resulted in an increased c-myc mRNA level,
followed by an increase in DNA synthesis and
cell number, indicating that IL-6 may play a role
in the proliferation of these cells.80 Human
vascular smooth muscle cells express and
secrete IL-6 after IL-1 stimulation or during
proliferation.72 We have shown that IL-6 is
expressed in the porcine heart at least at the
mRNAlevel and its expression may be regulated
by ischemia±reperfusion.15 Furthermore, hy-
poxic cardiomyocytes have been shown to
produce IL-6 which could contribute to ventri-
cular dysfunction as observed after myocardial
ischemia and reperfusion.81 Hirano et al.78
reported that IL-6 was expressed in cardiac
myxoma cells at much higher levels than in
activated lymphocytes. There is now evidence
that in patients suffering from acute myocardial
infarction, IL-6 may affect the progression and
the healing process of this illness, because IL-6
serum levels seem to be elevated in these
patients.82 Recently, it was shown that mRNAs
encoding IL-6 and ICAM-1 were induced in
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were localized in viable myocytes adjoining the
necrotic infarct suggesting a highly regulated
process.83
Cytokines ± Mediators of
In¯ ammation in Ischemia and
Reperfusion
Avariety of cytokines including IL-1, IL-6 and IL-
8 as well as TNF-a have been proposed as
important mediators of myocardial ischemia±
reperfusion injury. For example, IL-1 was found
in the circulating monocytes within hours of
cardiopulmonary bypass.84 Maximal amounts of
IL-1 were observed 24 h after extracorporeal
circulation. In another related study, an elevated
level of plasma IL-6 was found in the patients
following bypass surgery.85 Serum levels of IL-6
have also been reported to be elevated in
patients after myocardial infarction.82 Our own
laboratory has demonstrated induction of both
IL-1aand IL-8 in circulating leukocytes of human
patients with peak levels at 24 h post bypass.86
Intravenous administration of IL-1 or TNF-a was
associated with cardiopulmonary dysfunction in
pigs subjected to cardiopulmonary bypass.87 A
monoclonal antibody to TNFa could block or
attenuate the cardiopulmonary dysfunction.88
While a growing body of evidence suggests a
role of cytokines in the in￿ammatory response
associated with myocardial ischemia and reper-
fusion, the mechanism of cytokine induction
remains speculative. It has been suggested that
ischemia and reperfusion cause the activation of
platelets and leukocytes as well as the activation
of complement which results in the formation of
C3a/C3a-des-Arg and C5a/C5a-des-Arg.89 In-
creased levels of C3a-des-Arg and C5a-des-Arg
were documented during coronary revascula-
rization.86 These complement-derived chemotac-
tic factors can further activate polymorpho-
nuclear leukocytes (PMN) as well as mono-
nuclear phagocytes which in turn, generate
excessive quantities of oxygen-derived free
radicals.90 The production of oxygen free radi-
cals in the ischemic reperfused myocardium is
well documented91 and free radicals are known
inducers of endogenous pyrogens such as IL-1.92
The activation and accumulation of PMNs are
now thought to be due to the generation of local
and systemic leukocyte chemotactic factors
(LCFs).93 IL-1 was initially thought to induce
chemotaxis, but is now shown not to possess
any chemotactic activity; the previously re-
ported chemotactic activity of this cytokine is
believed to be due to contamination with other
LCFs such as IL-8. IL-8 is one of the most
powerful PMN and T -lymphocyte chemotactic
factors; it can stimulate PMN adherence to
endothelial cells and extracellular matrix pro-
teins which is a manifestation of ischemic
reperfusion injury.94 IL-8 can also illicit a respira-
tory burst with the generation of oxygen free
radicals and a rapid but transient increase in the
free intracellular Ca2+ concentration.95 It is quite
possible that the hydroxyl radical (OH·) forma-
tion associated with ischemia±reperfusion is
mediated in part through IL-8 formation. Among
many potential sources of in vivo OH· forma-
tion, PMNs represent the most signi￿cant one.96
The involvement of PMNin the pathogenesis of
myocardial ischemia reperfusion injury has been
implicated in many previous studies. During
phagocytosis, PMN release their granule con-
tents with massive production of many toxic
oxygen metabolites including oxygen free radi-
cals. Very recently, phagocytosing PMNs were
found to express high levels of IL-8 mRNA. There
is no doubt that IL-8 represents the most power-
ful neutrophil chemotactic activity; it is also
highly selective for PMNs. The newly expressed
IL-8 can further stimulate the degranulation and
respiratory burst of neutrophils, resulting in the
formation of superoxide anions and hydrogen
peroxide and thus potentiate a cascade of
reactions leading to a gross in￿ammatory re-
sponse.
Another mechanism by which cytokines may
potentiate in￿ammatory response in the is-
chemic reperfused heart is by enhancing phos-
pholipase A2 activity. TNF-a was found to
stimulate phospholipase A2 and release arachido-
nic acid leading to the biosynthesis of cyclooxy-
genase products.97 Activation of phospholipase
A2 in concert with the accumulation of arachi-
donic acid and production of prostaglandin
endoperoxides and hydroperoxides are the sali-
ent features of myocardial ischemic reperfusion
injury.98 Many of the cyclooxygenase products
including hydroperoxides and endoperoxides
are known mediators of in￿ammation.
Interestingly, many of the cytokines including
IL-1, IL-6 and TNF-a have been shown to
stimulate nitric oxide (NO) production.99 Re-
ports exist to indicate that IL-1 may impair the
myocardium by inhibiting intrinsic regulatory
mechanisms by modulating the b-adrenergic
control of cardiac L-type Ca2+ current and that
this effect is mediated by the L-arginine ±nitric
oxide pathway. 100 IL-1 can uncouple the b-
receptor from adenylyl cyclase through a pertu-
ssis toxin-sensitive substrate such as the Gi
protein. The generation of NO has been sug-
gested to play a role in the impairment of
ventricular function during cytokine-mediated
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have demonstrated a role for NO in myocardial
ischemic reperfusion injury, 101,102 and there is
evidence that IL-1 activates a dexamethasone-
sensitive L-Arg/NO pathway.103 The ￿nding that
cytokines induce NO production 102,103 futher
supports the role for NOin the augmentation of
the cytokine-mediated in￿ammatory response.
Cytokines Mediate Adaptive
Response in Ischemic and
Reperfused Myocardium
A number of recent studies have indicated that
molecular and cellular adaptation to oxidative
stress makes the heart more tolerant to ischemic
reperfusion injury. 104 It is generally believed that
such oxidative stress adaptation is mediated by
the induction of several stress proteins including
antioxidants and HSPs. At low doses, cytokines
such as IL-1 and TNF-a can induce the expres-
sion of HSPs by adapting the heart to oxidative
stress.59 IL-1 and IL-6 can also induce antioxidant
enzymes such as Mn2+ SOD).105 IL-1 has been
found to function as a therapeutic agent when
used at low doses;106 and it possesses the ability
to downregulate its own receptors thus explain-
ing the protective role of IL-1 to lethal chal-
lenges by hypoxia or ischemia.107
One of the prominant features of myocardial
ischemic reperfusion injury is the development
of oxidative stress. Ischemia and reperfusion
potentiate the oxidative stress by at least two
mechanisms. Firstly, natural antioxidative en-
zymes including Mn2+ SOD, catalase, glutathione
(GSH) peroxidase and GSH-reductase are re-
duced during ischemia and reperfusion. 108 Sec-
ondly, it is well known that oxygen-derived free
radicals are produced during reperfusion of
ischemic myocardium.99 The results of our own
study has demonstrated that pretreatment of
heart with low doses of IL-1 can reduce oxida-
tive stress and enhance several antioxidant
enzymes as well as HSP-27 in the ischemic
reperfused myocardium.109 Such oxidative stress
adaptation was associated with the reduction of
ischemic reperfusion injury suggesting a strong
correlation between the induction of oxidative
stress inducible proteins and reduction of is-
chemic reperfusion injury by IL-1.
In summary, ischemia and reperfusion induce
the expression of cytokines such as IL-1, IL-6, IL-
8 and TNF-a. These cytokines presumably play a
role in the in￿ammatory response associated
with ischemic reperfusion injury. However, a
small amount of IL-1 or TNF-a appear to induce
HSPs and antioxidants that make the heart more
tolerant to subsequent lethal ischemic injury.
Taken together, it is tempting to speculate that
ischemia±reperfusion-induced induction of cyto-
kines re￿ects the adaptive response of the heart
to the oxidative stress. In order to summarize
Myocardial ischemia/reperfusion
Generation of C3a/C5a
High Leukocyte
activation
Free radicals
Ischemic
reperfusion
injury
Oxidative stress
2
Induction of
IL-8 IL-6 IL-1 TNF
Low
Induction of
HSPs/Antioxidants
Adaptive response
Reduced ischemic-reperfusion injury
FIG. 1. A model of the role of cytokines in myocardial ischemia and reperfusion.
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we propose a speculative model depicting the
role of cytokines in myocardial ischemia and
reperfusion (Fig. 1). We believe that in short
ischemic episodes when there is a lower level of
stress cytokine levels are low and the heart can
enhance its own defense by inducing HSPs and
antioxidants; if, however, the amount of stress is
large, the induced cytokines are overwhelmed
by the stress and a cascade of in￿ammatory
reactions is initiated which leads to ischemic
reperfusion injury.
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